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Polybrominated diphenyl ethers (PBDEs) were used as flame-retardant additives
starting 1965 and were recently withdrawn from commerce in North America and
Europe. Approximately 1/5 of the total U.S. population were born when environmental
concentrations of PBDE plateaued at their maximum. Accumulating evidence suggests
that developmental exposures to PBDE may result in long-lasting programming of
liver metabolism. In this study, CD-1 mice were exposed prenatally or neonatally to
1mg/kg body weight of 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47), and changes in
liver histology, transcriptome, and liver-blood balance of triglycerides were analyzed in
10 months old male offspring. In both exposure groups, long-term reprogramming of
lipid metabolism was observed, including increased liver triglycerides and decreased
blood triglycerides, and altered expression of metabolic genes in the liver. Significant
upregulation of lipid influx transporter Cd36 2.3- and 5.7-fold in pre- and neonatal
exposure groups, respectively was identified as a potential mechanism of blood/liver
imbalance of triglycerides. Analysis of our and previously published all-genome gene
expression data identified changes in expression of ribosomal protein genes as a
transcriptomic signature of PBDE exposure. Further comparison of our new data
and published data demonstrate that low doses (0.2 mg/kg body weight) of PBDE
induce long-lasting up-regulation of ribosomal genes, suppression of Cd36 in liver and
increase circulating triglycerides in blood, while moderated doses (≥1 mg/kg body
weight) produce opposite long-lasting effects. To conclude, this study shows that an
environmentally relevant developmental exposures to BDE-47 permanently alter lipid
uptake and accumulation in the liver, with low andmoderate doses having opposite effect
on liver transcriptomics and triglyceride balance. Similar effects of pre- and neonatal
exposures point at hepatocyte maturation as a sensitive window of the liver metabolism
programming. These results suggest that PBDE exposure may be an important factor
increasing risks of cardio-vascular disease and non-alcoholic fatty liver disease via
modulation of liver/blood balance of lipids. The translational relevance of these findings
for human remain to be studied.
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INTRODUCTION
Polybrominated diphenyl ethers (PBDEs) are a group of
ubiquitous and persistent chemical compounds that include 209
congeners. PBDEs are highly lipophilic xenobiotics (1, 2) with
a half-life of 1.8–6.5 years in human tissues (3). PBDEs persist
in the environment due to pollution by industrial chemicals
and biosynthesis in natural ecosystems. The manufacturing of
commercial products containing PBDEs began in 1965 (4) and
synthetic PBDEs were widely used as flame-retardant additives
in a range of products, including building materials, electronics,
furnishings, motor vehicles, airplanes, plastics, polyurethane
foams, and baby pajamas. Production of PBDEs was banned in
Europe in 2003 because of concerning toxicological evidence (5).
In the US PBDEs were voluntarily withdrawn from commercial
use by industry by 2013 (6). Before these decisions were made
PBDEs increased exponentially in human blood, breast milk and
tissues (7), including fetal tissues (8) over a 30 years period.
In Europe, the discontinued use of PBDEs led to a decrease
in environmental concentrations in the recent years. However,
an epidemiological study of 1,253 women in California suggests
that PBDE concentrations continue to rise in North America
(9). This on-going persistence of PBDE exposure in humans
can be attributed to many factors, including, the prevalence
of PBDE in waste and recycling sites, indoor use of products
containing PBDEs (10), global circulation of PBDE toward
the Northern Hemisphere, biosynthesis of PBDE by microflora
of the marine environment including γ-proteobacteria (11),
and endosymbiotic microflora of benthic sponges (12–15) and
high bioaccumulation and bioconcentration of PBDEs in food
chains (16). Younger generations of Americans that were
exposed in utero and during early postnatal life to the highest
environmental doses of PBDE account for approximately one-
fifth of the US population (17, 18). The long-term consequences
of developmental exposures to PBDE for this population are not
well-understood.
In the general population, exposures to highly lipophilic
environmental xenobiotics usually peak during fetal and early
postnatal development, due to the active transfer of lipophilic
compounds from the mothers’ storage depots through cord
blood and breast milk (19, 20). Additional factors that lead
to an increased exposure during the early postnatal period are
the ingestion of PBDE-containing household dust by toddlers
(21) and high food intake per kilogram of body weight by
toddlers (22). As a result, breastfeeding toddlers have several-fold
higher plasma levels of PBDEs than their mothers (23). Thus,
PBDE exposure is highest during early stages of development (in
utero and early postnatal) when biological plasticity is high and
even modest exposures to environmental stressors may result in
dramatic and long-term health effects (24–26).
The ability of chemical compounds to disrupt lipid
metabolism in liver has been known for many years (27).
The term “metabolic disruptor” was suggested recently
by a group of experts to characterize the growing list of
environmental compounds that are able to alter metabolism
in the mammalian organism (26). Another term, “toxicant-
associated steatohepatitis” (TASH) was coined (28) to
characterize cases of fatty-liver disease in highly exposed
chemical workers. The ability of chemical compounds to
produce long lasting changes in lipid metabolism following
developmental short-term exposures is poorly understood,
although this type of exposure is relevant for many lipophilic
environmental xenobiotics. In our recent study, we reported
that mice exposed to 0.2 mg/kg body weight of 2,2′,4,4′-
tetrabromodiphenyl ether (BDE-47), the most prevalent PBDE
congener in human samples, from gestation day 8 (GD8) till
postnatal day 21 (PND21), develop long lasting suppression of
fatty acid (FA) translocase Cd36 in hepatocytes (18), a membrane
receptor responsible for FA uptake. Changes in expression of
this gene were concordant with increased blood triglycerides
in exposed animals (18). Increased level of blood lipids is the
primary risk factor for heart attack, which is the most common
cause of mortality in the developed world, with more than
700,000 deaths attributed to the disease in the US annually
(29). Exposure of significant part of the general population to
PBDE during early stages of development together with the
ability of PBDE to program lipid metabolism in a mammalian
organism by early life exposures raises significant concerns about
metabolic health of young Americans and suggests a need for
additional studies, to examine the relations between early life
PBDE exposures and permanent changes in liver metabolism.
In this study we analyze developmental windows sensitive to
liver metabolism programming by PBDE using a mouse model.
We report that exposures to 1 mg/kg body weight of BDE-47
during prenatal or neonatal windows produce similar changes
in 10 months old mice. These changes include altered liver
transcriptome, including increased expression of Cd36, altered
balance of triglycerides between blood and liver and hepatic
steatosis-like phenotype. All these effects are opposite in direction
in comparison with effects observed in our previous study (18),
where mice were exposed to 0.2 mg/kg body weight of BDE-47
perinatally, suggesting complex dose-response relationships for
developmental programming of liver metabolism by PBDEs.
MATERIALS AND METHODS
Animals and Treatment
Timed pregnant CD-1 mice were obtained from Charles River
Laboratories (Kingston, NY, USA) at pregnancy day 6 and
housed in a temperature (23 ± 2◦C)- and humidity (40 ± 10%)-
controlled environment, with a 12-h light/dark cycle, and food
and water available ad libitum. The dams were assigned to one
of three treatment groups (n = 10 per group) based on weight
match. The control group was exposed to vehicle—tocopherol-
stripped corn oil (MP Biomedicals, Solon, OH) from pregnancy
day 8 till postpartum day 21. The prenatal exposure group
received 1 mg/ml solution of BDE-47 (AccuStandard, Inc., New
Haven, CT; 100% purity) in tocopherol-stripped corn oil from
pregnancy day 8 through delivery and then vehicle only from the
day of delivery till postpartum day 21. Neonatal exposure group
received only vehicle from gestational day 8 till delivery and was
then exposed to 1 mg/ml solution of BDE-47 in tocopherol-
stripped corn oil through postpartum day 21. Either vehicle or
BDE-47 solution was orally administered daily via micropipette
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in a volume of 1 µl/gram body weight (BW) resulting in
exposures to 1 mg/kg BW/day during pre- or neonatal periods.
This method of exposure is routinely used in our laboratory
as a substitution of oral gavage, which induces a significant
stress response by the endocrine system, which may interfere
with the evaluation of endpoints of interest (30). The dams
delivered naturally, and the litters were not culled to maintain
consistency of nutrient distribution among the same number of
fetuses/pups at pre- and postnatal periods, and to avoid catch-
up growth (31). The dams and pups were kept together until
weaning on postnatal day (PND) 21, when the male and female
pups were separated. One randomly selected male pup per litter
was euthanized using cervical dislocation on PND300 between 9
and 11 a.m. following 2 h of fasting. Tissue samples were collected
immediately upon euthanasia. Blood samples were centrifuged
at 3,000 g for 10min and serum was collected and stored at -
80◦C. Liver was snap-frozen in liquid nitrogen and stored at
-80◦C. Only male pups were used for further analysis to avoid
the interaction of measured health outcomes with hormonal
fluctuations due to estrus cycle. Other male and female pups
were used in a different study. All procedures met the guidelines
of the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and this study was approved by the
Institutional Animal Care and Use Committee at University of
Massachusetts, Amherst.
RNA Extraction and Sequencing
Total RNA was isolated from liver samples using TRIzol reagent
(Invitrogen) and quantified using a NanoDrop 1000 instrument
(Thermo Fisher Scientific, Wilmington, DE). RNA quality was
assessed using Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA). Samples of RNA isolated from liver tissue
with integrity values >9 were used for library preparation. RS-
122-2101-TruSeq R© Stranded mRNA LT-SetA kit (Illumina, San-
Diego, CA) was used to isolate intact poly(A)+ RNA from 4
µg of total RNA and to construct strand-specific libraries with
multiplexing indexes. The quality and purity of the libraries were
assessed using the Agilent 2100 Bioanalyzer. The concentration
of the libraries was measured using Qubit 3.0 fluorometer
(Life Technologies, Carlsbad, CA). High-throughput sequencing
was performed using NextSeq500 sequencing system (Illumina,
San-Diego, CA) in the Genomic Resource Laboratory of the
University of Massachusetts, Amherst. cDNA libraries were
single-end sequenced in 76 cycles using a NextSeq 500 Kit v2
(FC-404-2005, Illumina, San-Diego, CA) in one multiplex run
(3–4 samples per exposure group). All sequencing data were
uploaded to the GEO public repository and GEO were assigned
series accession number GSE115143.
Analysis of Mouse RNA-seq Data
Read filtering, trimming and de-multiplexing were performed
using the BaseSpace cloud computing service supported
by Illumina (https://basespace.illumina.com/home/index).
Furthermore, the preprocessed reads were mapped to the
reference mouse genome (MM10) using TopHat 2 aligner (32).
Aligned reads were then used for assembly of novel transcripts
with Cufflinks 2.1.1 and differential expression of novel and
reference transcripts with Cuffdiff 2.1.1 (33). Differential
expression datasets were further used for gene set enrichment
analysis (GSEA, www.broadinstitute.org/gsea). This approach
is particularly effective for the identification of biologically
significant changes in gene expression that are associated with
relatively small effects across multiple members of a gene set
(34). The details of the method and statistical approaches used by
GSEA are described elsewhere (35, 36). We used GSEA against
theHallmark, KEGG and Reactome collections of datasets. Short-
lists of significantly differentially expressed genes were identified
by applying thresholds of 2-fold differential expression and false
discovery rate (FDR) q ≤ 0.05. These lists were analyzed using
DAVID Functional Annotation Clustering tool (37) and Disease
and BioFunctions tool of Ingenuity Pathway Analysis (38)
with default settings. To explore further liver lipid metabolism
mechanisms affected by BDE-47 we inspected changes in
expression of genes, that encode key enzymes of lipid trafficking,
de-novo synthesis and/or disposal (39, 40). The following
genes were selected for analysis (see Supplemental File 1):
fatty acid uptake proteins—fatty acid translocase (FAT; gene
Cd36) and fatty acid uptake proteins (FATP; Slc27a genes);
de-novo synthesis of fatty acids—acetyl-CoA carboxylase
(ACC; genes Acaca and Acacb) and fatty acid synthase (FAS;
gene Fasn); synthesis of triglycerides—glycerol-3-phosphate
acyltransferase (GPAT; gene Gpam), 1-acylglycerol-3-phosphate
O-acyltransferase (AGPAT; Agpat genes), diacylglycerol O-
acyltransferase (DGAT; Dgat genes), lipin (LIPIN; Lpin genes),
mannoside acetylglucosaminyltransferase (MGAT; Mgat1
genes), and adiponutrin (gene Pnpla3); oxidation of fatty
acids—acyl-CoA synthetase (ACS; Acsl, Acsm, and Acss genes),
carnitine palmitoyltransferase (CPT; genes Cpt1a, Cpt1b, Cpt1c,
Cpt2), adipose triglyceride lipase (ATGL, gene Pnpla2), and
3-hydroxy-3-methylglutaryl-coenzyme A synthase (HMG-CoA;
Hmgcs genes); very low density lipoprotein (VLDL) secretion—
apolipoprotein B (gene Apob), microsomal triglyceride transfer
protein (MTP, gene Mttp), carboxylesterase (CES; genes Ces1d,
Ces1g, and Ces3a), and cell death-inducing DFF-45-like effector
B (gene Cideb).
RT-qPCR
The RNA-seq results were validated using RT-qPCR for selected
genes: Cd36, Abcd2, Prelid2, Apoa4, Fabp4, Fgl1, Gdpd3, and
Hao2. These gene were selected based on the following criteria
(1) they were significantly regulated in both exposure groups
based on RNA-seq results and (2) they encode proteins
important for liver metabolic function. RT-qPCR was done
using independent set of samples, six per exposure group. Total
RNA was purified of genomic DNA contamination using DNase
(RQ1 RNAse-free DNAse, Cat. # M610A, Promega, Madison,
WI), and reverse transcribed using the High Capacity cDNA
Reverse Transcription Kit (Cat.# 4368814, Applied Biosystems,
Vilnus, Lithuania). Using free online software Primer3Plus
(http://primer3plus.com/cgi-bin/dev/primer3plus.cgi), forward
and reverse primers were designed to anneal different exons
spanning long intron (Table 1). The housekeeping gene (B2m)
was selected from genes that were not regulated in our RNA-
seq dataset, with the consideration of its ubiquitous presence in
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TABLE 1 | Quantitative reverse transcription polymerase chain reaction (RT-qPCR) validation of RNA-seq genes for selected differentially expressed genes.
Fold change
Gene qPCR primers Prenatal exposure Postnatal exposure
RNA-seq qPCR RNA-seq qPCR
Cd36 TGTGTTTGGAGGCATTCTCA
TTTGAAAGCAGTGGTTCCTTC
2.25 2.01 5.58 4.99
Abcd2 TGTGGAGCAGCTGTGGACTA
CATAGCCTGCTTTGGACCAT
11.00 9.76 5.90 5.37
Prelid2 TGTTCCAGTACCCCTTCGAG
TTCCACAGTTTTTACAGAGATGACA
−5.28 −6.11 −5.13 −6.20
Apoa4 AGTGAGGAGCCCAGGATGTT
CACCTGGTCCGAAGTGACCT
−3.48 −2.98 −3.81 −3.45
Fabp4 AATGTGTGATGCCTTTGTGG
CACTTTCCTTGTGGCAAAGC
−6.68 −5.34 −6.06 −7.01
Fgl1 GTGGATGGACTGAGCCTAGC
TTCCCATTCTTCCCACTGAG
−2.41 −2.55 −6.59 −5.17
Gdpd3 CCTTTTGTCTCCATCCCTGA
CCACAGCGAAATGGGAAGTA
16.91 11.39 6.23 5.86
Hao2 GAGGCAGCTTGATGAGGTTC
CCCACCATCCATGTACACTTC
4.86 5.12 7.73 6.03
B2m CCGGCCTGTATGCTATCCAG
TGTTCGGCTTCCCATTCTCC
Housekeeping gene
different cell types. A triplicate of 5 µl real-time PCR reactions,
each containing iTaq Universal SYBR Green Supermix (Cat 172-
5124, BioRad), primers, and cDNA template were loaded onto a
384-well plate and run through 40 cycles on a CFX384 real time
cycler (Bio-Rad Laboratories, Inc). The data were analyzed using
the manufacturer’s CFX manager software, version 3.1. Relative
quantification was determined using the11Cq method (41).
Protein Expression of Cd36
Expression of Cd36 was analyzed by western blotting in
liver samples of male offspring euthanized on PND300. Liver
samples were lysed in T-PER tissue protein extraction buffer
(ThermoFisher Scientific, Cat. # 78510) containing protease
and phosphatase inhibitors cocktail (ThermoFisher Scientific,
Cat. # 78442). A microplate-based BCA Protein Assay Kit
(ThermoFisher Scientific, Cat. # 23227) was then used to
determine protein concentrations. Western blot analyses were
performed after separating the proteins on 4–20% SDS-PAGE
gels (Bio-Rad, Cat. # 456-1094) and transferring them onto
a PVDF membrane (0.2µm) under wet conditions using a
Biorad mini trans-blot cell. Anti-Cd36 (1:2000, Cell Signaling,
Cat. #14347) and anti-Actin (1:2000, Cell Signaling, Cat. #
4970) primary antibodies were used at indicated dilutions.
Proteins were visualized using secondary antibody conjugated
with HRP (1:5000, Abcam, Cat. # ab6721), and Pierce ECL
enhanced chemiluminesence reagent (ThermoFisher Scientific,
Cat. # 32106). Western blot densitometry was quantified using
Image Studio Lite Ver 5.2 software.
Histological Analysis
Oil Red O staining was performed in accordance with the
protocol for frozen tissue described elsewhere [IHS (42)]. Liver
samples were sectioned at 10µm for lipid staining. Sections were
fixed in 10% neutral buffered formalin for 10min, rinsed with
water, and immersed in 100% propylene glycol for 5min. Slides
were stained with Oil Red O solution (Sigma) for 10min at
60◦C, and placed in 85% propylene glycol for 5min followed
by a rinse in distilled water. Slides were counterstained with
Harris’ hematoxylin for 30 sec, washed in running tap water and
coverslipped using Kaiser’s Glycerin Jelly. Sections were imaged
through a Zeiss Axio Observer Z1 inverted light microscope with
ZEN imaging software, at ×10 and ×40 magnification. Images
were captured at 88,000 dpi using the AxioCam 506 color digital
camera.
Triglycerides in Blood and Liver
To quantify changes in triglycerides concentrations were
measured in blood and liver samples of 10 months old mice using
a Triglyceride Colorimetric Assay Kit (Cat. # 10010303, Cayman
Chemical, Ann Arbor MI). Ten biological replicates (one pup
per litter) were analyzed per exposure group. Each biological
replicate was analyzed in triplicate.
Reanalysis of Published Transcriptional
Datasets
Changes in liver gene expression for many individual genes, as
well as for groups of metabolic genes, which were observed in this
current study were opposite in direction to the changes reported
in our previous study (18). We hypothesize that differences in
exposure protocols may have been responsible for the opposite
effects in the direction of change of the gene expression in
livers of exposed animals. To test this hypothesis we analyzed
changes in expression of ribosomal genes, a group of genes
that is most sensitive to PBDE exposure according to our
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current and previously published data (18), in transcriptomic
datasets obtained from toxicological experiments with PBDE.
The search for transcriptomic datasets was completed on June 1,
2017. Specifically, we searched Gene Expression Omnibus (GEO,
http://www.ncbi.nlm.nih.gov/geo/) and ArrayExpress (https://
www.ebi.ac.uk/arrayexpress/) genomic data depositories using
the following key words: PBDE, BDE, polybrominated, diphenyl
ether, and flame retardant. We also ran a search in the PubMed
(http://www.ncbi.nlm.nih.gov/pubmedn) using a combination of
the words PBDE, BDE, and polybrominated diphenyl ether with
one of the following: gene expression, transcriptome, microarray,
RNA-seq, and genomic. All selected papers were then checked
for the presence of all-genome gene expression analysis and, if
positive, for links to the original gene expression data. As a result
of this search, we identified transcriptomic datasets produced
by our research group (18, 43, 44) and another research group
(45). Experimental designs of these studies are summarized in
Table 2. To address changes in expression of ribosomal genes we
used GSEA with the “KEGG Ribosome” gene set. This gene set
includes 88 human genes of ribosomal proteins and RNA, and is
curated by Kyoto Encyclopedia of Genes and Genomes (KEGG,
http://www.genome.jp/kegg/).
Statistical Analysis
All statistical analyses were performed using SPSS Statistics 22
software. ANOVA with subsequent Dunnett’s test were used to
compare body weights and triglyceride values in blood and liver
between exposed and control groups. T-test was used to compare
western blot densitometry for CD36 protein expression between
control and each exposed group. Correlation coefficient was
calculated to determine reproducibility of RNA-seq results using
RT-qPCR for selected genes and to compare effects of pre- and
neonatal exposures on gene expression.
RESULTS
We found no significant relationship between litter size and
exposure to BDE-47, with the number of pups varying from 9
to 15 per litter. On PND300, body weights of male animals were
58.5 ± 1.9 g in the control group, 52.5 ± 1.4 g in the prenatally
exposed group (p = 0.02), and 56.6 ± 1.9 g in the neonatally
exposed group (p = 0.09). All data are mean ± SE and p-values
are for comparison with controls.
Pre-and Neonatal Exposures to BDE-47
Induce Similar Transcriptomic Changes in
Livers of 10 Months Old Mice
We analyzed using an RNA-seq approach transcriptional changes
in liver tissue of 10 months old male mice. Sequencing was
completed with an average of 45 million reads per sample
and more than 90% of the reads aligned to the reference
genome. After filtering out transcripts that did not correspond
to any of known identifiers (genes, non-coding RNAs) and
those that had LogFPKM ≤ 0 in both conditions (control and
exposed), lists of genes with differential expression values were
generated for both exposure groups. These lists consisted of
10,962 transcripts for the prenatal exposure group and 11,035
transcripts for the neonatal exposure group. Short lists of the
TABLE 2 | Gene set enrichment analysis (GSEA) of ribosome dataset in transcriptomic studies of PBDE effect in rodents and details of experimental design of these
studies.
Model Sex Tissue Exposure
chemical
Daily dose,
mg/kg/
body weight
Exposure duration
(ED–embryonic day,
(PND–postnatal day)
PND for
outcome
Gene expression analysis
approach
Normalized enrichment
score/Nominal p-value
KEGG* ribosome
Source
Rat Male liver DE-71** 50 ED6-PND22 22 Affymetrix Rat Genome 230
2.0 Array
−2.14/0.000 (45)
Rat Female liver DE-71** 50 ED6-PND22 22 Affymetrix Rat Genome 230
2.0 Array
−1.98/0.000 (45)
Rat Male liver DE-71** 50 ED6-PND91 91 Affymetrix Rat Genome 230
2.0 Array
−1.97/0.000 (45)
Rat Male liver BDE-47 0.2 ED15-PND21 27 Illumina BeadChips
RatRef-12
1.39/0.034 (43)
Rat Female brain
frontal
lobes
BDE-47 0.2 ED15-PND21 41 Illumina BeadChips
RatRef-12
1.40/0.033 (44)
CD1
mice
Male liver BDE-47 0.2 ED8-PND21 21 Illumina TruSeq RNA-Seq 1.60/0.006 (18)
CD1
mice
Male liver BDE-47 0.2 ED8-PND21 140 Illumina TruSeq RNA-Seq 3.21/0.000 (18)
CD1
mice
Male liver BDE-47 1 ED8-ED21 300 Illumina TruSeq RNA-Seq −2.49/0.000 Current
study
CD1
mice
Male liver BDE-47 1 PND1-PND21 300 Illumina TruSeq RNA-Seq −1.59/0.019 Current
study
*KEGG, Kyoto Encyclopedia of Genes and Genomes. **DE-71 is a commercial mix of PBDE, which includes primarily the tetra- through penta-PBDEs and a small component of
hexa-BDE.
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significantly differentially expressed genes were generated using
cut-off thresholds of 2-fold change in expression and a false
discovery rate (FDR) q ≤ 0.05. RNA-seq results were confirmed
by RT-qPCR for select genes (Table 1). Correlation coefficients
between values of gene expression change measured by RNA-
seq and RT-qPCR were 0.98 in both exposure groups. Short lists
of genes that were differentially expressed following prenatal or
neonatal exposure consisted of 176 and 191 genes, respectively.
These lists overlapped for 88 genes (Figure 1A). Correlation
coefficient between values of gene expression change in the
merged list of 279 genes significantly altered in either exposure
group was 0.87. Most of these genes that did not overlap were
still altered in the same direction in both exposure groups
although with lower significance and fold change (Figures 1B,C).
In fact only 10 out of 191 non-overlapping genes were altered in
different directions and correlation coefficient was 0.52 for the
merged list of non-overlapping genes between exposure groups.
Developmental Exposure to BDE-47 Alters
Blood/Liver Balance of Triglycerides and
Leads to Lipid Accumulation in Livers of 10
Months Old Mice
We analyzed concentrations of triglycerides in serum and in
livers of exposed and control animals. We also used Oil Red O
staining of liver sections to visualize triglyceride droplets. In both
exposed groups, liver tissue had a higher number of lipid droplets
in hepatocytes (Figures 2A,B). Triglycerides concentrations in
serum were decreased in both exposure groups compared to
the control group (2.81 ± 0.32 mg/ml in the control group;
1.87 ± 0.15 mg/ml, p = 0.019 in the prenatal exposure group;
and 2.18 ± 0.21 mg/ml, p = 0.131 in the neonatal exposure
group)—Figure 2D. Concentrations of triglycerides in the liver
were increased in both exposure groups (8.23 ± 0.88 mg/g
in the control group; 10.31 ± 0.79 mg/g, p = 0.102 in the
prenatal exposure group; and 13.18 ± 1.46 mg/g, p = 0.015
in the neonatal exposure group)—Figure 2E. The ratio of liver
to serum triglyceride concentrations was significantly higher in
both exposed groups (2.94 ± 0.12 in the control group; 5.57 ±
0.27, p = 3.3E-07 in the prenatal exposure group; and 5.99 ±
0.23, p = 1.3E-08 in the neonatal exposure group)—Figure 2F.
All data shown are mean ± SE and p-values are for comparison
with controls.
Pre-and Neonatal Exposures to BDE-47
Alters Expression of Genes Responsible for
Lipid Metabolism and Protein Biosynthesis
in Livers of 10 Months Old Mice
Gene sets enriched with Normalized Enrichment Score >1.6,
nominal p ≤ 0.05 and FDR q ≤ 0.2 were selected for further
analysis. Thus, we used a more stringent criteria than that
FIGURE 1 | Changes in liver gene expression in 10 months old mice are highly overlapping in groups exposed prenatally only and neonatally only to 1 mg/kg/body
weight BDE-47: (A)–overlap in lists of significantly (FDR q ≤ 0.05) 2-fold differentially expressed genes; (B)–heat-map and unsupervised hierarchical clustering based
on merged list 280 genes significantly (FDR q ≤ 0.05) 2-fold differentially expressed in pre- and/or postnatally exposed groups; (C)–changes in expression of
non-overlapping genes (89 + 103 genes) in pre- and neonatal exposure groups, for majority of genes direction of change is the same in both groups.
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FIGURE 2 | Developmental exposure to BDE-47 results in altered triglyceride concentrations in hepatocytes and blood of 10 months old mice. (A–C)–representative
liver tissue sections stained with Oil Red O and Harris’ hematoxylin (×400): (A)–control group, (B)–prenatal exposure group, (C)–neonatal exposure group. Lipid
droplets are stained in orange. (D,E)–triglyceride concentrations in blood and liver, respectively. (F)–liver to serum triglyceride ratio. All data are Mean ± SE, n =
10/exposure group, ANOVA followed by Dunnett’s test, *p < 0.05 when compared with control group.
recommended by GSEA developers (FDR q ≤ 0.25, http://
software.broadinstitute.org/gsea/doc/) for a more exclusive focus
on significantly altered biological processes. Gene sets that
satisfy these criteria in at least one exposure group (prenatal
or neonatal) are shown in Table 3 and Supplemental File 2.
All negatively enriched gene-sets from KEGG and Reactome
collections and a few from the Hallmark collection point
to a suppression of mRNA processing, translation and post-
translational processing of protein, such as: KEGG: Ribosome
(Figure 3A) and Spliceosome; Reactome: Translation, Peptide
Chain Elongation, Protein Metabolism, mRNA Metabolism and
Protein Folding; Hallmark: Protein Secretion and others. The
gene set of an mTORC1 pathway, which is a major pathway
of protein synthesis control, was also negatively enriched
(Hallmark: mTORC1 Signaling). Gene sets from Hallmark
also include negatively enriched gene-sets that are related to
cellular stress (Unfolded Protein Response, DNA Repair), cell
cycle progression, apoptosis and cellular transformation (MYC
Targets V1 and V2), and immune response (Interferon Gamma
and Interferon Alpha Response). Significant Hallmark gene-
sets relevant for lipid metabolism include negatively enriched
Cholesterol Homeostasis gene set and positively enriched Bile
Acid Metabolism gene set. Cholesterol Homeostasis gene set
was negatively enriched partly due to decreased expression of
genes encoding proteins responsible for lipid transport into cells
(Plscr1, Fabp5, Lpl) and genes encoding enzymes of cholesterol
biosynthesis (Sqle, Hmgcs1, Idi1, Mvd). Some of the latter genes
encode for rate-limiting enzymes of different stages of cholesterol
synthesis (Sqle, Hmgcs1). The positively enriched Bile Acid
Metabolism gene set was due to the increased expression of many
genes participating in bile acid biosynthesis, including many key
enzymes of the pathway (Cyp7a1, Cyp46a1, Cyp27a1, Cyp8b1,
Akr1d1, Slc27a2, Slc27a5, Amacr, Hsd17b4).
DAVID Functional Annotation Clustering analysis was done
separately for upregulated and downregulated genes from the
shortlists of significantly altered genes in the prenatally and
postnatally exposed groups. The most enriched clusters are
shown in the Table 4. The “Cytochrome P450” cluster was
positively enriched in the postnatal exposure group due to
the upregulation of cytochrome genes, largely in family 2.
The “Transmembrane and transmembrane transport” cluster
was positively enriched in both exposure groups and included
up-regulated solute carrier genes, ABC transporters, oxysterol
binding proteins, desmogleins, Cd36 and others. Negatively
enriched categories include “endoplasmic reticulum” (postnatal
exposure group only), “acute-phase response, HDL, fatty acid
binding,” “metallothionein,” and “extracellular, glycoprotein.” The
analysis of annotations of genes in the cluster “endoplasmic
reticulum” showed their functional heterogeneity. Most of
these genes grouped in one of three functions: vesicle
transport to Golgi (Ehd4, Golt1b, Lrrc59, Sec23b, Tmed3,
Tmed9), response to ER-stress (Creb3l2, Creld2, Dnajb9,
Hyou1, Manf, Sdf2l1), and fatty acid metabolism (Acsl4,
Aldh3a2, Elovl3, Elovl7, Fndcb3, Insig2, Mrap, Mrap2). The
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TABLE 3 | Top GSEA enriched gene-sets in livers of 10 months old mice exposed pre- or neonatally to BDE-47.
Gene set Prenatal exposure Neonatal exposure
NES NOM p-val FDR q-val NES NOM p-val FDR q-val
HALLMARK COLLECTION OF GENE-SETS
Unfolded protein response −2.06 0.000 0.003 −1.98 0.000 0.003
MYC targets V2 −2.04 0.000 0.002 −1.81 0.006 0.017
MYC targets V1 −2.01 0.000 0.002 −2.00 0.000 0.004
DNA repair −1.93 0.000 0.006 −1.62 0.011 0.054
Cholesterol homeostasis −1.66 0.010 0.060 −1.80 0.008 0.018
MTORC1 signaling −1.61 0.005 0.074 −1.64 0.004 0.052
Interferon gamma response −1.39 0.050 0.234 −2.04 0.000 0.006
Interferon alpha response −1.38 0.086 0.205 −1.84 0.001 0.016
Protein secretion −1.22 0.181 0.365 −1.65 0.007 0.052
Bile acid metabolism 1.62 0.020 0.409 2.16 0.000 0.056
KEGG COLLECTION OF GENE-SETS
Ribosome −2.49 0.000 0.000 −1.59 0.019 0.266
Spliceosome −1.92 0.000 0.087 −1.86 0.000 0.187
RNA polymerase −1.90 0.007 0.097 −1.48 0.072 0.302
Protein export −1.85 0.014 0.107 −2.04 0.002 0.085
REACTOME COLLECTION OF GENE-SETS
Translation −2.62 0.000 0.000 −1.87 0.000 0.187
SRP dependent cotranslational protein
targeting to membrane
−2.56 0.000 0.000 −1.81 0.000 0.196
Influenza viral RNA transcription and replication −2.53 0.000 0.000 −1.64 0.004 0.247
3 UTR mediated translational regulation −2.51 0.000 0.000 −1.62 0.009 0.256
Peptide chain elongation −2.46 0.000 0.000 −1.51 0.031 0.292
Influenza life cycle −2.40 0.000 0.000 −1.64 0.009 0.247
Nonsense mediated decay enhanced by the
exon junction complex
−2.33 0.000 0.000 −1.47 0.034 0.301
Metabolism of proteins −2.31 0.000 0.000 −1.81 0.000 0.199
Activation of the mRNA upon binding of the
cap binding complex and EIFS and subsequent
binding to 43S
−2.29 0.000 0.001 −1.52 0.035 0.290
Formation of the ternary complex and
subsequently the 43S complex
−2.25 0.000 0.001 −1.54 0.036 0.279
Metabolism of mRNA −2.20 0.000 0.004 −1.46 0.016 0.307
Metabolism of RNA −2.18 0.000 0.004 −1.57 0.003 0.271
mRNA splicing minor pathway −2.11 0.000 0.014 −1.74 0.015 0.224
Protein folding −1.95 0.000 0.072 −1.77 0.009 0.213
mRNA splicing −1.93 0.000 0.081 −1.75 0.003 0.219
Activation of chaperone genes by XBP1S −1.89 0.006 0.100 −2.03 0.000 0.094
NES, normalized enrichment score; NOM p, nominal p-value; FDR q, false discovery q-value. All numbers for gene sets enriched with nominal p ≤ 0.05 and FDR q ≤ 0.2 are shown in
bold.
“Acute-phase response, HDL, fatty acid binding” and the
“extracellular, glycoprotein” clusters were enriched due mostly
to the decreased expression of genes encoding serum lipid-
binding proteins. This includes orosomucoid genes (Orm1,
Orm2, and Orm3), which are carriers of basic and neutrally
charged lipophilic compounds, high-density lipoprotein (HDL)
associated apolipoproteins (Saa1, Saa2 and Saa3), chylomicron
associated apolipoprotein A-IV (Apoa4) and fatty acid binding
proteins (Fabp4 and Fabp5). The “Metallothionein” cluster
was negatively enriched in both exposure groups due to the
downregulation of threemetallothionein proteins (Mt1,Mt2, and
Mt4).
We performed an IPA Disease and BioFunctions analysis with
default settings. Initially, this analysis was performed for three
lists of differentially regulated genes: genes altered in animals
exposed to BDE-47 in utero, genes altered in animals exposed
to BDE-47 neonatally, and a merged list of genes regulated
in both groups. The results of this analysis were very similar
for all three gene lists, therefore we present here only data for
the merged list of genes (see Supplemental File 3 for details).
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FIGURE 3 | GSEA enrichment of “KEGG Ribosome” gene set in mouse liver: (A)–mice were exposed prenatally to 1 mg/kg body weight BDE-47 and gene expression
analyzed on PND300; (B)–mice were exposed perinatally to 0.2 mg/kg body weight BDE-47 and gene expression analyzed on PND140 (18). GSEA plot legend:
1-running enrichment score for the gene set; 2-vertical lines show where the members of the gene set appear in the ranked list of genes; 3 and 4-ranked list of
differentially expressed genes from the most up-regulated (left of each plot) to the most downregulated (right of each plot). Regulation is shown in the heat-bar (3) and
in the bar plot (4).
TABLE 4 | Top enriched DAVID clusters in livers of 10 months old mice exposed
prenatally or neonatally to BDE-47.
Cluster of enriched
terms
Prenatal exposure
group
Neonatal exposure
group
ES* Benjamini p ES* Benjamini p
POSITIVELY REGULATED FUNCTIONS
Cytochrome P450 3.13 6.0E-1–2.0E-4 6.14 5.6E-1–1.8E-9
Transmembrane,
transmembrane transport
2.22 9.8E-1–5.2E-4
NEGATIVELY REGULATED FUNCTIONS
Endoplasmic reticulum 4.82 5.8E-3–4.3E-5
Acute-phase response,
HDL, fatty acid binding
1.51 9.9E-1–3.2E-1 3.89 9.8E-1–9.9E-5
Metallothionein 3.62 7.5E-1–1.6E-2 3.50 3.1E-1–7.9E-3
Extracellular, glycoprotein 1.86 8.1E-1–1.5E-1 3.43 1.0E0–1.1E-6
*ES, enrichment score.
The “Concentration of lipid” was the most significantly enriched
category (p = 7.1E-08). The “Hepatic steatosis” cluster was one
of the most significantly enriched categories with high predicted
activation (p = 4.69E-07, activation z-score = 2.89), while
“Atherosclerosis” was among the most significant categories with
predicted suppression (p= 5.25E-06, activation z-score=−2.35;
Figure 4).
To explore what mechanisms of liver lipid metabolism altered
by BDE-47 may be responsible for increased triglycerides in
livers of exposed animals we analyzed changes in expression
of key enzymes of lipid trafficking, de-novo synthesis and/or
disposal (Supplemental File 1). Cd36 is the only gene form
this list that was significantly altered in both exposed groups,
with 2.3- and 5.6-fold increase in expression in prenatally and
postnatally exposed animals, respectively. Higher magnitude of
change of Cd36 in postnatally exposed animals correspond to
higher concentrations of triglycerides in their livers. Expression
of Cd36 protein was also significantly increased in liver of animals
from both exposed groups as confirmed by western blot data
(Figure 5).
Low and Moderate/High Exposures to
PBDE Regulate Expression of Metabolic
Genes in Opposite Directions
In both the current study, and our previous study (18), ribosomal
genes represented one of the most sensitive groups of genes
that underwent coordinated changes in expression following
PBDE exposure. However, changes in expression of ribosomal
genes had an opposite direction in these studies. Similarly,
many other important metabolic genes, including Cd36 were
significantly differentially expressed in both studies but the
direction of change was different. To test whether variables
in the experimental protocol may have contributed to the
observed opposite effects in expression of metabolic genes,
we analyzed changes in the expression of ribosomal genes
in transcriptomic datasets obtained from previously published
toxicological experiments with PBDE (18, 43–45) as described
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FIGURE 4 | IPA Disease and BioFunctions analysis: hepatic steatosis and atherosclerosis—significantly positively and negatively enriched categories in livers of 10
months old mice developmentally exposed to 1 mg/kg body weight BDE-47.
FIGURE 5 | Expression of Cd36 protein is increased in livers of 10 months old mice exposure to BDE-47 during prenatal or neonatal development: (A)–expression of
Cd36 measured by western blot; (B)–quantification of Cd36 protein expression (Mean ± SE, n = 3/exposure group, p-value is for T-test).
in Reanalysis of Published Transcriptional Datasets. The results
of this analysis are summarized in Table 2. In short, (i)
the ribosomal gene set was enriched in GSEA analysis with
nominal p-value <0.05 in all reanalyzed datasets, supporting
our observation that coordinated changes in ribosomal gene
expression represent a molecular signature of PBDE exposure.
(ii) In the studies that used rats and mice, similar exposures
produced similar changes in ribosomal gene expression. For
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example perinatal exposure to 0.2 mg/kg BW BDE-47 in Wistar
rats and in CD-1 mice significantly positively enriched ribosomal
dataset in liver tissue (18, 43). (iii) One study focused on gene
expression in the brain frontal lobes (44) and it showed similar
changes in ribosomal gene expression as studies that used similar
exposures to analyze gene expression in liver tissue (43, 44).
(iv) Finally, the opposite effects were observed in studies using
0.2 mg/kg BW BDE-47 (18, 43, 44) and studies using 1 mg/kg
BW BDE-47 (current study) or 50 mg/kg BW DE-71 (45)—a
commercial mix of PBDE, which includes primarily the tetra-
through penta- PBDEs and a small component of hexa-BDE.
DISCUSSION
We have found that both prenatal and neonatal exposure to
1 mg/kg body weight of BDE-47 result in similar changes in
expression of metabolic genes in 10 months old mouse liver,
suggesting permanent reprogramming of the liver metabolism in
both exposure groups. This reprogramming includes increased
expression of Cd36 and other lipid transporters and decreased
expression of serum lipid-binding proteins which is a likely
mechanistic explanation of the observed shift in the balance
of triglycerides toward their reduced concentrations in the
blood and increased concentrations in the liver. Long-lasting
or permanent shift in liver metabolism, leading to excessive
accumulation of triglycerides in the liver, may be a risk factor
for the development of liver steatohepatitis—the most common
form of chronic liver disease among adults and children (46, 47)
with 33% to 88% prevalence (48–51). Liver steatohepatitis is
a risk factor for type 2 diabetes, dyslipidemia, hypertension,
cardiovascular and kidney disease, liver cirrhosis, hepatocellular
carcinoma, and mortality (52–57).
Relevance of our Dosing Paradigm
In our previous study (58), exposure of pregnant rats to 0.2mg/kg
body weight of BDE-47 resulted in 234.3 ng BDE-47/g lipid in
adipose tissue of dams and 1,054.7 ng BDE-47/g lipid in adipose
tissue of pups. These concentrations are comparable with those
of the North American human population (mean concentration
in adipose tissue of adult subjects = 399 ng/g lipids) (2). Given
that the rate of BDE-47 elimination is around 10 times higher
in mice than in rats (59, 60) the exposure used in this study
may also be relevant to that of the North American human
population. To further increase the relevance of our exposure
paradigm to human exposures, we dosed animals during pre-
or neonatal periods since human PBDE exposure peaks during
the perinatal period of life due to the transport of PBDE via cord
blood and breast milk (19, 20, 22), higher rates of dust ingestion
(21), and higher food intake per kilogram of body weight in
toddlers (22).
Long Lasting Programming of Liver
Metabolism
In our previous studies, we have demonstrated that perinatal
exposures to low doses (0.2 mg/kg body weight) of BDE-
47 may produce long lasting changes in gene expression in
rodent livers. In our rat, study expression of many metabolic
genes including genes of cholesterol metabolism and ribosomal
proteins, were significantly altered 1 week after the last day of
exposure (43). Blood cholesterol was also increased in exposed
rats. In a recent study with CD-1 mice similar changes in
liver gene expression were observed on postnatal day 140,
∼4 months after the last day of exposure (18). Exposed mice
had significantly increased blood triglycerides. These findings
indicate that metabolic reprogramming of liver by developmental
exposure to PBDE is likely permanent. A long-lasting change
in liver lipid metabolism by PBDEs is also supported by
the current study as it demonstrates altered expression of
metabolic genes in liver and increased accumulation of liver
triglycerides 10 months after the last day of exposure. A
review of extant toxicological evidence linking exposures to
different chemicals with hepatic steatosis and steatohepatitis
(27) did not list any evidence of liver lipid accumulation in
adult organism resulting from developmental exposure. Thus,
developmental programming of liver metabolism described in
this study is a novel potential risk factor for fatty liver diseases
development.
Sensitive Exposure Windows
In previous studies, the perinatal window of exposure, spanning
from part of gestation and postnatal development until weaning,
was used to study programming effects of PBDE for the
liver metabolism (18, 43, 61). In the current study, we
aimed to narrow down the sensitive developmental window
of liver programming by using prenatal-only and postnatal-
only exposures. Surprisingly, both exposed groups developed
very similar shift in expression of metabolic genes including
upregulation of lipid transporter Cd36 and suppression of genes
encoding ribosomal proteins in the liver. Both exposure groups
also had similar shifts in the blood-liver balance of triglycerides,
including decreased serum triglycerides and increased liver
triglycerides, although triglycerides accumulation in the liver was
more pronounced in the neonatal exposure group. Thus, our
results demonstrate that the sensitive developmental window of
the liver metabolism reprogramming by BDE-47 spans across
pre- and neonatal periods of development, i.e., likely corresponds
to the period of hepatocyte maturation, which starts at gestation
day 18.5 and covers postnatal development at least till postnatal
day 45 (62–64). Postnatal exposure used in our experiment covers
longer period of hepatocyte maturation than prenatal exposure,
which only interferes with the beginning of this process. That fact
may explain higher accumulation of triglycerides in the livers of
postnatally exposed animals. It should be mentioned that BDE-
47 that accumulated in the bodies of fetuses in the prenatal
exposure group was not fully eliminated from the organisms by
the time of delivery and could affect somemolecular mechanisms
during the neonatal period, resulting in similar effects in both
exposure groups. Given that the half-life of BDE-47 in mice is
around 3–4 days (59, 60) we assume that “carry over” of BDE-47
from prenatal life to postnatal life in the prenatal exposure group
could have had health consequences only during first few days of
neonatal life.
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Molecular Mechanisms Underlying Altered
Liver/Blood Balance of Triglycerides
It was shown previously that major process that contributes to
lipid accumulation in liver is fatty acids uptake by hepatocytes
(39, 65, 66), although de novo lipogenesis, triglyceride synthesis,
as well as disposal of fatty acids in a form of oxidation and/or
VLDL secretion may contribute to triglyceride concentrations
in liver. To explore, perturbation of which process may be
responsible for the observed accumulation of triglycerides in our
study, we analyzed changes in expression of the key enzymes
(Supplemental File 1) involved in lipid uptake, biosynthesis and
disposal. Increased expression of Cd36 was the only enzyme from
this list that was significantly upregulated in both exposed groups
at the level of gene expression. Upregulation of Cd36 was also
confirmed at the level of protein expression, suggesting that this
change may be the major causative factor responsible for the
altered balance of the liver/blood triglycerides. This hypothesis
is additionally supported by the concordance in the magnitude
of Cd36 expression and triglycerides concentrations in livers
of exposed animals, so that higher upregulation of Cd36 in
postnatally exposed animals (5.7-fold) is concordant with higher
increase in concentration of triglycerides (168%) in this group as
compared with smaller change in Cd36 expression (2.3-fold) and
triglyceride concentration (125%) in prenatal exposure group.
Previous research demonstrates that overexpression of Cd36may
significantly increase fatty acid uptake in liver. Cd36 upregulation
induced by in vivo adenoviral delivery of the gene to the livers
of mice was sufficient to increased hepatic triglyceride storage
and dyslipidemia in mice (67). Cd36 expression is increased
in humans with NAFLD (68–70). Decreased rate of VLDL
secretion may also contribute to increased triglycerides in the
livers and decreased in blood of exposed mice. Genes of major
enzymes involved in VLDL secretion (Apob, Mttp, Ces1d, Ces1g,
Ces3a, Cideb) were not altered significantly, however many
genes responsible for VLDL trafficking between endoplasmic
reticulum (ER) and Golgi apparatus (Ehd4, Golt1b, Lrrc59,
Sec23b, Tmed3, and Tmed9) and genes involved in binding
of lipids in blood (Orm1, Orm2, Orm3, Saa1, Saa2, Saa3,
Apoa4, Fabp4, and Fabp5) were significantly downregulated.
Triglycerides and other lipid components are synthesized in
smooth ER and combine with apolipoprotein B at the junction
of smooth and rough ER. The nascent particles are then
transferred to the Golgi apparatus for further processing and
secretory VLDL vesicles are subsequently released from the
Golgi (39, 71, 72). Thus, interruption of ER-Golgi trafficking
may slow down VLDL secretion by hepatocytes. Decreased
expression of genes encoding serum lipid-binding proteins may
also contribute to decreased concentration of triglycerides in
blood.
Opposite Effects of Different Dosing
Protocols
As previously mentioned our recent study showed that CD-
1 mice exposed perinatally to 0.2 mg/kg body weight BDE-
47 (Table 2) had significantly upregulated genes of ribosomal
proteins (Figure 3B), significantly downregulated expression of
Cd36, and almost 2-fold increased concentration of triglycerides
in blood (18). Other studies have shown similar effects of genes
of ribosomal proteins being upregulated in the livers and brain
frontal lobes of rats exposed to the same concentration of BDE-
47 perinatally (43, 44). However, experimental data published
by Dunnick and others (45) demonstrate opposite effect, genes
of ribosomal proteins was the most negatively enriched gene-
set. Dunnick and others exposed rats to 50 mg/kg body weight
of DE-71, a commercial mix of PBDE, from embryonic day 6
continuously throughout the animals’ lifetime until euthanasia
(PND22 or PND91). Given that a significant shift (although
in different directions) in expression of ribosomal genes was
found in all transcriptomic studies of PBDE effects (Table 2), we
used this “molecular signature” of PBDE to determine whether
differences in experimental design were responsible for opposite
outcomes. Existing studies used different animal models, timing
of exposure, exposure dose, timing of outcome measurement,
time interval between exposure and outcome measurement and
chemical compound (BDE-47 or DE-71). Interestingly, same
dose of BDE-47 produced similar changes in ribosomal gene
expression in different tissues (43, 44), in different models (18,
43, 44) and in tissues collected at different time-intervals after
exposure (18, 43, 44). However, the same compound used at
higher dose produced opposite effect in the current study. This
FIGURE 6 | Proposed mechanism of metabolic reprograming by PBDE:
PBDEs or their metabolites bind to the plasma membrane associated p30
TRα1 and induce an increase in intracellular Ca2+ concentration, which leads
to activation of the NO-cGMP-PKGII signaling cascade and the
phosphorylation and activation of the SHP1/SHP2 phosphatase complex. This
complex activates SRC which in turn activates MEK-ERK and PI3K-AKT
signaling. Both cascades merge on and suppress tuberous sclerosis complex
(TSC), which is a potent mTORC1 suppressor. Lipogenesis and adipogenesis
are regulated by mTORC1 mainly via SREBP1/2 and PPARγ transcription
factors that control the expression of genes involved in fatty acid and
cholesterol synthesis, lipid uptake and storage. Additionally mTORC1 directly
phosphorylates/activates S6K1 which phosphorylates/suppresses IRS1
causing insulin resistance.
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effect was similar to the one induced by high dose of PBDE mix
(45). Thus, data presented in Table 2 suggest, that the critical
parameter responsible for the direction of change of ribosomal
gene expression is likely the dose of the compound. Future
research should include targeted dose-response experiments to
test this hypothesis.
Concern for Human Health
As discussed in the introduction, approximately one-fifth of
the US population (∼60 million) experienced their perinatal
development when concentrations of PBDE plateaued at their
highest environmental levels (17, 18). If the PBDE-induced
programming effects described in the current study are seen
in humans, we may anticipate long-term adverse consequences
of developmental exposures to PBDE. Our study demonstrates
that different exposure scenarios in rodents may result in the
shift in liver-blood lipid balance in either direction. Our studies
indicate, that smaller doses suppress lipid uptake by the liver,
resulting in triglyceride accumulation in serum. Higher doses
of PBDE induce lipid uptake and accumulation in the liver.
Importantly, both smaller and higher doses discussed here are
relevant for the general population. Fatty changes in liver were
previously shown in juvenile mice exposed for 28 days to 0.45
mg/kg body weight of BDE-47 (73). Liver steatosis associated
with increased expression of Cd36 was recently shown in mice
exposed to low doses of BDE-47 perinatally and further kept
on high fat diet for 14 weeks (74). Liver fatty degeneration
was also demonstrated in adult rats exposed to high dose
(2,000 mg/kg body weight) of pentaBDE (75, 76) and in
prepubertal rats exposed to high doses (300 and 600 mg/kg body
weight) of decaBDE (77). The link between PBDE exposures
and lipid imbalance was never tested in human population
studies.
Tight regulation of fatty acids (FA) uptake by the liver is
the major process that contributes to a healthy balance of
lipids between the blood and the liver (65, 66). Abnormal
shifts in this balance in either direction may result in increased
morbidity and mortality risks. An increase in the uptake of
fatty acids and accumulation of triglycerides in lipid droplets
results in NAFLD. NAFLD increases the risk of type 2 diabetes,
dyslipidemia, hypertension, cardiovascular and kidney disease,
liver cirrhosis, hepatocellular carcinoma, and mortality (52–57).
Treatment options for NAFLD have very limited efficacy. On the
other hand, decreased uptake of fatty acids by the liver may result
in hyperlipidemia and atherosclerosis—the primary risk factors
for heart attack, which is the most common cause of mortality in
the developed world (29, 78–80).
Molecular Mechanisms of Liver
Metabolism Programming by PBDE
Molecular mechanisms of metabolic effects of PBDE remain
poorly understood. Previously, we demonstrated that BDE-47
activates mTOR (mechanistic target of rapamycin) signaling
in mouse livers and in human hepatocellular carcinoma cells
(18). mTOR is a serine/threonine protein kinase that emerged
over the last decade as a critical signaling node that links
nutrient and energy sensing to the coordinated regulation of
cellular growth and metabolism (81, 82). Thus, mTOR plays
a central role in lipid homeostasis (83, 84). One of the best
characterized functions of mTOR pathway consists in the
regulation of ribosomal biogenesis (85, 86). In the current
study “mTORC1 signaling” and “ribosome” were among the
most negatively enriched categories (Table 3) supporting our
hypothesis, that mTOR pathway is involved in the long-lasting
response to PBDE (18). The mTOR complex one (mTORC1)
integrates signals from PI3K-AKT and RAS-ERK pathways upon
their activation by receptor tyrosine kinases in response to
insulin and insulin-like growth factors (81, 87). A recent study
demonstrated the ability of BDE-47 and BDE-85 to activate
PI3K-AKT signaling (88) in a thyroid receptor alpha dependent
manner. Involvement of TRα and AKT points at recently
described non-genomic pathway of thyroid hormone signaling
(89) in which binding of T3 to the plasma membrane-associated
p30 isoform of TRα1 activates the nitric oxide (NO)/cyclic
guanosine monophosphate (cGMP)/protein kinase G II (PKGII)
signaling cascade and results in the phosphorylation/activation
of the SHP1/SHP2 phosphatase complex. Activation of the
tyrosine kinase SRC by this complex results in activation of
MEK-ERK and PI3K-Akt signaling. Given that PBDEs are
well-characterized thyroid disruptors (90–94), we propose the
following hypothesis to link developmental PBDE exposures to
long-lasting programming of livermetabolism (Figure 6): PBDEs
and/or their metabolites interact directly with thyroid receptors
and activate downstream PI3K-AKT and MEK-ERK signaling to
induce mTORC1 activity; changes in mTORC1 activity during
critical windows of liver development change liver metabolic
settings and induce long-lasting alterations in lipid and other
metabolism. Additional mechanistic research is needed to test
this hypothesis.
CONCLUSIONS
We have found that prenatal or neonatal exposures to an
environmentally relevant dose (1 mg/kg body weight) of BDE-
47 result in permanent reprogramming of the liver metabolism
in both exposure groups. The similarity in responses of both
exposure groups indicate that the sensitive window of liver
metabolism programming spans pre- and postnatal period of
development. Observed reprogramming included changes in
expression of genes involved in lipid and other metabolism,
which resulted in reduced concentrations of triglycerides in
the blood and increased concentrations of triglycerides in
the liver. Opposite directional changes in expression of many
metabolic genes and levels of circulating triglycerides were
observed in comparison with previous studies, which used a
lower exposure dose (0.2 mg/kg body weight). Both exposure
doses are relevant for the general population. If similarity
of toxic effects and dose-response relationships between mice
and humans will be proven in future research it will indicate
that the range of existing and past environmental exposures
could produce changes in lipid metabolism in both directions
in the general population. The shift in blood-liver balance
of lipids may be associated with health conditions, such
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as NAFLD and atherosclerosis. Based on this study and
previously published data, we propose that metabolic effects
of developmental exposures to PBDE are mediated by the
mTORC1 signaling pathway. Species-specific differences in
the involved pathways need to be further investigated to
assess the translational relevance of our findings. Additional
research is needed to test the mechanistic considerations of this
study, establish dose-response relations between developmental
exposures and lipid metabolism in adulthood, and elucidate
developmental metabolic effects of PBDE in the general
population.
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